Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637556 | PMC |
| http://dx.doi.org/10.1089/thy.2008.0162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting pathological ERK1/2 signaling in cancer and beyond.
Trends Mol Med
September 2025
Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany; Leibniz-Institut für Analytische Wissenschaften (ISAS) e.V., 44139 Dortmund, Germany. Electronic address:
Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects, and resistance mechanisms - has expanded our knowledge of both the physiological and pathological functions of ERK1/2 and could thus provide potential alternative therapeutic strategies.
View Article and Find Full Text PDFRare phenotypes of white coat color in Simmental calves: genetic causes of syndromic forms of albinism and depigmentation.
Mol Genet Genomics
September 2025
Institute of Genetics, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
The aim of this study was to investigate three unrelated Simmental calves with atypical white coat color, identify potential genetic causes using a trio-based whole-genome sequencing approach, and assess the prevalence of the identified variants in the breed. Several inherited alleles affecting coat color, ranging from fawn to red spotted and white-headed, have been described in Simmental cattle originating from Switzerland. However, no genetic variant has yet been associated with an almost completely white coat in this breed.
View Article and Find Full Text PDFLeft Atrial Appendage Occlusion Devices Focused on Complications of Therapy.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation for stroke prevention in atrial fibrillation (AF), especially in patients at high bleeding risk. While generally safe, LAAO involves procedural and postprocedural risks. The most serious complication is pericardial effusion or tamponade; other periprocedural risks include stroke, device embolization, vascular injury, major bleeding, and air embolism.
View Article and Find Full Text PDFAudiological outcomes of the Cochlear Osia 2 bone conduction system implanted under expanded indications in a pediatric population.
Int J Audiol
September 2025
Otolaryngology-Head and Neck Surgery, ENT Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Objective: Evaluate the audiological outcomes of the Cochlear Osia 2 Bone Conduction System implanted in children ages 5-11 years old.
Design: A pivotal, prospective, open-label, multicentre clinical trial to expand access to the Osia 2 system to children ages 5-11 years old.
Study Sample: Children aged 5-11 years old who presented with either (1) a conductive or mixed hearing loss where the pure tone average bone conduction threshold (measured at 500, 1000, 2000, and 3000 Hz) was ≤ 55 dB HL or (2) single-sided deafness where the ear to be implanted had a profound sensorineural hearing loss and the pure tone average air conduction threshold (measured at 500, 1000, 2000, and 3000 Hz) in the contralateral ear was ≤ 20 dB HL.
[Chimeric antigen receptor T-cells for patients with hematologic malignancies].
Z Rheumatol
September 2025
Medizinische Klinik V (Hämatologie, Onkologie und Rheumatologie), Deutsches Konsortium für Tumorerkrankungen (DKTK) und Nationales Zentrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg (UKHD), Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
The targeted and personalized cell and gene therapy with autologous chimeric antigen receptor (CAR) transduced T‑cells (CAR T‑cells) has become established as the standard therapy for patients with B‑cell diseases, such as CD-19 positive leukemia and lymphomas and B‑cell maturation antigen (BCMA) positive multiple myeloma (MM). This therapy has been approved in Europe since 2018 and is administered in more than 50 clinics in Germany. With increasing experience and expertise in understanding of the principles of action and underlying mechanisms as well as mitigation of side effects have significantly improved.
View Article and Find Full Text PDF